Global Green (GOGC) 10-Q 14 Nov 13 2013 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Sep. 30, 2013	Nov. 11, 2013
Document And Entity Information	'	'
Entity Registrant Name	'GLOBAL GREEN INC.	'
Entity Central Index Key	'0001522724	'
Document Type	'10-Q	'
Document Period End Date	30-Sep-13	'
Amendment Flag	'false	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock, Shares Outstanding	'	745,761,432
Document Fiscal Period Focus	'Q3	'
Document Fiscal Year Focus	'2013	'

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Sep. 30, 2013	Dec. 31, 2012
Current assets	'	'
Cash and cash equivalents	$171,400	$4,027
Prepaid expenses	750	1,125
Due from shareholders	2,000	'
Total current assets	174,150	5,152
Intangible asset, net	5,879	6,131
Total assets	180,029	11,283
Current liabilities:	'	'
Accounts payable and accrued expenses	27,756	30,180
Due to shareholders	500	500
Convertible advance - related party	263,000	'
Total liabilities	291,256	30,680
Shareholders' deficit:	'	'
Preferred stock; no par value; 100,000,000 shares authorized; no shares outstanding at September 30, 2013 or December 31, 2012	'	'
Common stock; $.00001 par value; 3,000,000,000 shares authorized; 745,761,432 shares issued and outstanding at September 30, 2013 or December 31, 2012	7,458	7,458
Additional paid in capital	285,573	285,573
Deficit accumulated during the development stage	-404,258	-312,428
Total shareholders' deficit	-111,227	-19,397
Total liabilities and shareholders' deficit	$180,029	$11,283

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parentheticals) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Shareholders' deficit:	'	'
Preferred stock, par value	'	'
Preferred stock, authorized	100,000,000	100,000,000
Preferred stock, outstanding	'	'
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, authorized	3,000,000,000	3,000,000,000
Common stock, issued	745,761,432	745,761,432
Common stock, outstanding	745,761,432	745,761,432

Consolidated_Statement_of_Oper

Consolidated Statement of Operations (Unaudited) (USD $)	3 Months Ended		9 Months Ended		111 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013
Income Statement [Abstract]	'	'	'	'	'
REVENUES	'	'	'	'	'
OPERATING EXPENSES	'	'	'	'	'
Testing for U.S. Department of Agriculture's approval	'	'	'	'	137,800
Professional fees	15,494	15,798	30,516	60,943	157,518
General and administrative	20,873	4,079	48,533	17,861	78,558
Consulting fees	'	5,000	'	10,000	10,200
Stock transfer agent fees	485	1,199	1,570	2,081	8,172
Interest expense	3,408	'	10,908	'	10,908
Amortization	84	84	252	252	952
Bank fees	'	25	51	75	150
Total operating expenses	40,344	26,185	91,830	91,212	404,258
NET LOSS	($40,344)	($26,185)	($91,830)	($91,212)	($404,258)
Net loss per share applicable to common stockholders - basic and diluted (in dollars per share)	$0	$0	$0	$0	'
Weighted average number of shares outstanding - basic and diluted (in shares)	745,761,432	745,761,432	745,761,432	745,761,432	'

Consolidated_Statement_of_Equi

Consolidated Statement of Equity (Unaudited) (USD $)	Common Stock	Additional Paid in Capital	Accumulated During the Development Stage	Total
Balance at Jul. 12, 2004	'	'	'	'
Balance (in shares) at Jul. 12, 2004	'	'	'	'
Increase Decrease In Stockholders Equity [Roll Forward]	'	'	'	'
Share issuance	314	-314	'	'
Share issuance (in shares)	3,141,597	'	'	'
Balance at Dec. 31, 2004	314	-314	'	'
Balance, (in shares) at Dec. 31, 2004	3,141,597	'	'	'
Increase Decrease In Stockholders Equity [Roll Forward]	'	'	'	'
Share issuance	'	'	'	'
Balance at Dec. 31, 2005	314	-314	'	'
Balance, (in shares) at Dec. 31, 2005	3,141,597	'	'	'
Increase Decrease In Stockholders Equity [Roll Forward]	'	'	'	'
Share issuance	'	'	'	'
Balance at Dec. 31, 2006	314	-314	'	'
Balance, (in shares) at Dec. 31, 2006	3,141,597	'	'	'
Increase Decrease In Stockholders Equity [Roll Forward]	'	'	'	'
Share issuance	'	'	'	'
Balance at Dec. 31, 2007	314	-314	'	'
Balance, (in shares) at Dec. 31, 2007	3,141,597	'	'	'
Increase Decrease In Stockholders Equity [Roll Forward]	'	'	'	'
Share issuance	'	'	'	'
Balance at Dec. 31, 2008	314	-314	'	'
Balance, (in shares) at Dec. 31, 2008	3,141,597	'	'	'
Balance at Dec. 31, 2009	314	-314	'	'
Balance (in shares) at Dec. 31, 2009	3,141,597	'	'	'
Increase Decrease In Stockholders Equity [Roll Forward]	'	'	'	'
Recapitalization due to 10 to 1 stock split	'	'	'	'
Recapitalization due to 10 to 1 stock split (in shares)	28,274,370	'	'	'
Stock based compensation	200	'	'	200
Stock based compensation (in shares)	20,000,000	'	'	'
Share issuance	6,831	'	'	6,831
Share issuance (in shares)	683,097,847	'	'	'
Net loss	'	'	-5,728	-5,728
Balance at Dec. 31, 2010	7,345	-314	-5,728	1,303
Balance, (in shares) at Dec. 31, 2010	734,513,814	'	'	'
Increase Decrease In Stockholders Equity [Roll Forward]	'	'	'	'
Share issuance	113	285,887	'	286,000
Share issuance (in shares)	11,247,618	'	'	'
Net loss	'	'	-191,800	-191,800
Balance at Dec. 31, 2011	7,458	285,573	-197,528	95,503
Balance, (in shares) at Dec. 31, 2011	745,761,432	'	'	'
Increase Decrease In Stockholders Equity [Roll Forward]	'	'	'	'
Net loss	'	'	-114,900	-114,900
Balance at Dec. 31, 2012	7,458	285,573	-312,428	-19,397
Balance, (in shares) at Dec. 31, 2012	745,761,432	'	'	'
Increase Decrease In Stockholders Equity [Roll Forward]	'	'	'	'
Net loss	'	'	-91,830	-91,830
Balance at Sep. 30, 2013	$7,458	$285,573	($404,258)	($111,227)
Balance, (in shares) at Sep. 30, 2013	745,761,432	'	'	'

Consolidated_Statement_of_Equi1

Consolidated Statement of Equity (Unaudited) (Parentheticals)	1 Months Ended
	31-May-10
Statement Of Stockholders Equity [Abstract]	'
Forward stock split ratio	'10-to-1 stock split

Consolidated_Statement_of_Cash

Consolidated Statement of Cash Flows (Unaudited) (USD $)	9 Months Ended		111 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013
CASH FLOWS FROM OPERATING ACTIVITIES:	'	'	'
Net loss	($91,830)	($91,212)	($404,258)
Adjustments to reconcile net loss to net cash from operating activities:	'	'	'
Amortization	252	252	952
Stock based compensation	'	'	200
Change in assets and liabilities:	'	'	'
Prepaid expenses	375	1,688	-750
Accounts payable and accrued expenses	-2,424	3,343	27,756
Due from shareholders	-2,000	'	-2,000
Due to shareholders	'	'	500
Net cash from operating activities	-95,627	-85,929	-377,600
CASH FLOWS FROM FINANCING ACTIVITIES:	'	'	'
Proceeds from share issuance	'	'	286,000
Proceeds from convertible advance -related party, net	263,000	'	263,000
Net cash from financing activities	263,000	'	549,000
NET CHANGE IN CASH	167,373	-85,929	171,400
CASH, beginning of period	4,027	103,360	'
CASH, end of period	171,400	17,431	171,400
SUPPLEMENTAL DISCLOSURE OF NONCASH ACTIVITIES:	'	'	'
Common stock issued for acquisition of Global Green International, Inc.	'	'	$6,831

NATURE_OF_ORGANIZATION

NATURE OF ORGANIZATION	9 Months Ended
	Sep. 30, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
NATURE OF ORGANIZATION	'
	NOTE 1         NATURE OF ORGANIZATION
	Global Green, Inc. (the “Company”) is a Florida Corporation incorporated on July 12, 2004 as a wholly owned subsidiary of Global Assets & Services, Inc.  In September 2004, the Company was spun out into a separate legal entity.  The Company changed its name from The Global Tech Assets, Inc. to Global Green, Inc. in April 2010 and its fiscal period end is December 31.
	The Company is in the development stage.  The principal activities during the development stage include organizing the corporate structure, implementing the Company’s business plan and raising capital.  Although the Company was formed in 2004, it did not have any operating activities until 2010.
	Under the Share Exchange Agreement executed on November 29, 2010, between the Company and Nutritional Health Institute, LLC ("NHIL"), the Company acquired 100% of the issued and outstanding stock of Global Green International, Inc. (“GGII”), a wholly owned subsidiary of NHIL. At the same time, the Company issued approximately 683 million shares of its common stock, representing 93% of the ownership of the Company, to NHIL. After the above mentioned acquisition as per the Share Exchange Agreement, the Company has become a majority-owned subsidiary of NHIL. As the effective control over GGII did not change, in accordance with Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) 805 Business Combinations, GGII is consolidated at its book value (See Note 4).  Prior to November 2010, GGII had no assets or operations, so there is no impact to the historical financial statements.
	GGII, a wholly-owned subsidiary of the Company, has been granted the exclusive worldwide rights (the “Licensing Agreement”) to manufacture, distribute, market and sell a Salmonella Antigen and Vaccine (the “Vaccine”).  The Licensing Agreement was executed between NHIL and GGII before the Company acquired the 100% ownership of GGII and is the only asset of GGII.
	In February 2011, the Vaccine has been entered into the final phase of becoming a United States Department of Agriculture (“USDA”) approved vaccine for the in ovo vaccination of chicken eggs to provide immunity against Salmonella bacteria. In May 2011, the United States Patent and Trademark Office granted a patent for the method and composition in the Vaccine. In August 2011, an additional patent was granted related to the vaccine.

GOING_CONCERN

GOING CONCERN	9 Months Ended
	Sep. 30, 2013
Going Concern [Abstract]	'
GOING CONCERN	'
	NOTE 2         GOING CONCERN
	These consolidated financial statements have been prepared on a going concern basis which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business for the foreseeable future.  As of September 30, 2013, the Company has incurred net losses of $404,258 since inception (July 12, 2004).
	Management’s plans include raising capital through the equity markets to fund operations and eventually, the generating of revenue through its business; however, there can be no assurance that the Company will be successful in such activities.  These consolidated financial statements do not include any adjustments relating to the recovery of the recorded assets or the classifications of the liabilities that might be necessary should the Company be unable to continue as a going concern.

SUMMARY_OF_SIGNIFICANT_ACCOUNT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]	'
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	'
	NOTE 3         SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	Basis of Presentation
	The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) on the accrual basis of accounting.  All significant intercompany accounts and transactions have been eliminated in consolidation.  The interim financial statements reflect all adjustments, which are, in the opinion of management, necessary in order to make the financial statements not misleading.
	Use of Estimates
	The preparation of financial statements in conformity with GAAP requires management to adopt accounting policies and make estimates and assumptions that affect amounts reported in the financial statements.  The significant accounting policies, estimates and related judgments underlying the Company’s financial statements are summarized below.  In applying these policies, management makes subjective judgments that frequently require estimates about matters that are inherently uncertain.
	Cash and Cash Equivalents
	The Company considers all investments with a maturity date of three months or less when purchased to be cash equivalents.  There were no cash equivalents at September 30, 2013 and December 31, 2012.
	Revenue Recognition
	The Company recognizes revenue on arrangements in accordance with Securities and Exchange Commission Staff Accounting Bulletin Topic 13, Revenue Recognition and FASB ASC 605-15-25, Revenue Recognition.  In all cases, revenue is recognized only when the price is fixed or determinable, persuasive evidence of an arrangement exists, the service is performed and collectability is reasonably assured. The Company did not report any revenues from inception to September 30, 2013.
	Earnings Per Share
	The Company has adopted ASC 260-10-50, Earnings Per Share, which provides for calculation of "basic" and "diluted" earnings per share. Basic earnings per share includes no dilution and is computed by dividing net income or loss available to common shareholders by the weighted average common shares outstanding for the period. Diluted earnings per share reflect the potential dilution of securities that could share in the earnings of an entity. Basic and diluted losses per share were the same at the reporting dates as there were no common stock equivalents outstanding at September 30, 2013 and December 31, 2012.
	Concentrations
	Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash.
	Occasionally, cash balances may exceed amounts insured by the Federal Deposit Insurance Corporation (“FDIC”).  Accordingly, the Company places its cash and cash equivalents with financial institutions considered by management to be of high credit quality.  At times, the Company’s cash balances may be in excess of the FDIC limits.
	Fair Value of Financial Instruments
	The Company adopted Statement of Financial Accounting Standards (“SFAS”) No. 157 Fair Value Measurements (“SFAS 157”), superseded by ASC 820-10, which defines fair value, establishes a framework for measuring fair value and expands required disclosure about fair value measurements of assets and liabilities. The impact of adopting ASC 820-10 was not significant to the Company’s financial statements. ASC 820-10 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820-10 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:
	Level 1 – Valuation based on quoted market prices in active markets for identical assets or liabilities.
	Level 2 – Valuation based on quoted market prices for similar assets and liabilities in active markets.
	Level 3 – Valuation based on unobservable inputs that are supported by little or no market activity, therefore requiring management’s best estimate of what market participants would use as fair value.
	In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety.  Our assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment, and considers factors specific to the asset or liability.  The valuation of our derivative liability is determined using Level 1 inputs, which consider (i) time value, (ii) current market and (iii) contractual prices.
	Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of September 30, 2013 and December 31, 2012.  The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments.  These financial instruments include cash, accounts payable, accrued expenses and advance.
	Income Taxes
	Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Additionally, the recognition of future tax benefits, such as net operating loss carryforwards, is required to the extent that realization of such benefits is more likely than not. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which the assets and liabilities are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income tax expense in the period that includes the enactment date.
	In the event the future tax consequences of differences between the financial reporting bases and the tax bases of the Company’s assets and liabilities result in deferred tax assets, an evaluation of the probability of being able to realize the future benefits indicated by such asset is required. A valuation allowance is provided for the portion of the deferred tax asset when it is more likely than not that some or all of the deferred tax asset will not be realized. In assessing the realizability of the deferred tax assets, management considers the scheduled reversals of deferred tax liabilities, projected future taxable income, and tax planning strategies.
	The Company files income tax returns in the United States and Florida, which are subject to examination by the tax authorities in these jurisdictions. Generally, the statute of limitations related to the Company’s federal and state income tax return is three years. The state impact of any federal changes for prior years remains subject to examination for a period up to five years after formal notification to the states.
	Management has evaluated tax positions in accordance with FASB ASC 740, Income Taxes, and has not identified any significant tax positions, other than those disclosed.
	Subsequent Events
	In accordance with FASB ASC 855, Subsequent Events, the Company evaluated subsequent events through November 11, 2013, the date the financial statements were available for issue.

INTANGIBLE_ASSET

INTANGIBLE ASSET	9 Months Ended
	Sep. 30, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
INTANGIBLE ASSET	'
	NOTE 4         Intangible Asset
	The Company accounts for its intangible asset in accordance FASB ASC 350 Intangibles—Goodwill and Other. The intangible assets consist of the Licensing Agreement and is carried at an allocated cost, less accumulated amortization. The Licensing Agreement was executed on November 29, 2010 between NHIL and GGII, before the Company acquired the 100% ownership of GGII as described in Note 1. The provisions in the License Agreement include the Company's responsibilities to protect the Vaccine information and to assume financial responsibilities for the acquisition of USDA approval of the Vaccine. The License Agreement has no expiration date, but is being amortized over the 20 year legal life of the related patent. As the effective control over GGII did not change after acquisition by the Company, in accordance with FASB ASC 805, Business Combinations, the License Agreement is consolidated at the book value.
	Components of intangible assets at the periods ended are as follows:
		September 30,	31-Dec-12
		2013
	License agreement	$6,831	$6,831
	Accumulated amortization	-952	-700
		$5,879	$6,131

TAXES

TAXES	9 Months Ended
	Sep. 30, 2013
Income Tax Disclosure [Abstract]	'
TAXES	'
	NOTE 5        TAXES
	The components of income tax expense for the periods ended are as follows:
		September 30,	September 30,	Inception to September 30,
		2013	2012	2013
	Current tax benefit	($34,528)	($34,296)	($152,002)
	Change in valuation allowance	34,528	34,296	152,002
		$ -	$ -	$ -
	The difference between income tax expense computed by applying the statutory federal income tax rate to earnings before taxes for the periods ended are as follows:
		September 30,	September 30,	Inception to September 30,
		2013	2012	2013
	Pretax loss at federal statutory rate	($31,222)	($31,012)	($137,449)
	State income benefit, net of federal benefit	-3,306	-3,284	-14,553
	Change in valuation allowance	34,528	34,296	152,002
		$ -	$ -	$ -
	The components of deferred taxes are as follows:
		September 30,	31-Dec-12
		2013
	Deferred income tax assets:
	Operating loss carryforwards	$152,002	$117,474
	Less: Valuation allowance	-152,002	-117,474
	Net deferred tax asset	$ -	$ -
	At September 30, 2013 and December 31, 2012, a valuation allowance was established for the entire amount of the net deferred tax asset as the realization of the deferred tax asset is dependent on future taxable income.
	At September 30, 2013, the Company had net operating loss carryforwards for tax purposes of $404,258, which will expire beginning in 2031, if not previously utilized.

EQUITY

EQUITY	9 Months Ended
	Sep. 30, 2013
Stockholders' Equity Note [Abstract]	'
EQUITY	'
	NOTE 6         EQUITY
	In April 2010, the Company authorized the issuance of up to 100,000,000 shares of Preferred Stock at no par value.  As of September 30, 2013 and December 31, 2012, no shares are issued or outstanding.
	In May 2010, the Company had a 10-to-1 stock forward split, changing its par value from $.0001 per share to $.00001 per share.  Right after the said stock split, the Company issued 20,000,000 shares of its common stock to certain shareholders for services rendered valued at $200.  This is recorded as a non-cash expense in the accompanying statement of operations.
	In November 2010, the Company issued approximately 683 million shares of common stock, representing 93% of the ownership of the Company, to NHIL. After the above mentioned issuance, the Company has become a majority-owned subsidiary of NHIL.
	On March 21, 2011, the Company completed a private placement of common stock to accredited investors and raised $286,000 of working capital.

RELATED_PARTY_TRANSACTIONS_AND

RELATED PARTY TRANSACTIONS AND COMMITMENTS	9 Months Ended
	Sep. 30, 2013
Related Party Transactions [Abstract]	'
RELATED PARTY TRANSACTIONS AND COMMITMENTS	'
	NOTE 7         RELATED PARTY TRANSACTIONS AND COMMITMENTS
	On January 2013, the Company entered into a convertible advance with the Company’s Chief Executive Officer and Chairman. The convertible advance, with a face value of $300,000, bears interest at 5% per annum and is payable on demand. The convertible advance is convertible, at the holder’s option, into the Company’s common or preferred shares based on the value of the shares at the execution date of the advance.  The convertible advance is valued at the greater of the face value of the advance or the fair value of the shares, if converted.  At September 30, 2013 and December 31, 2012, the convertible advance, was recorded at $263,000 and $0, respectively.   Accrued interest related to this advance was $10,908 and $0 at September 30, 2013 and December 31, 2012, respectively, and is included in accounts payable and accrued expenses on the balance sheet.
	Through its wholly-owned subsidiary, GGII, the Company has exclusive rights to the Licensing Agreement with NHIL, the Company’s majority shareholder.  In accordance with this agreement, GGII assumes the financial responsibility for the acquisition and maintenance of all patents, as well as USDA’s approval of the Vaccine.

CONTINGENCIES

CONTINGENCIES	9 Months Ended
	Sep. 30, 2013
Commitments and Contingencies Disclosure [Abstract]	'
CONTINGENCIES	'
	NOTE 8        CONTINGENCIES
	During the normal course of business, the Company may be exposed to litigation.  When the Company becomes aware of potential litigation, it evaluates the merits of the case in accordance with FASB ASC 450-20-50, Contingencies.  The Company evaluates its exposure to the matter, possible legal or settlement strategies and the likelihood of an unfavorable outcome.  If the Company determines than an unfavorable outcome is probable and can be reasonably estimated, it establishes the necessary accruals.  As of September 30, 2013, the Company is not aware of any contingent liabilities that should be reflected in the accompanying financial statements.

SUMMARY_OF_SIGNIFICANT_ACCOUNT1

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]	'
Basis of Presentation	'
	Basis of Presentation
	The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) on the accrual basis of accounting.  All significant intercompany accounts and transactions have been eliminated in consolidation.  The interim financial statements reflect all adjustments, which are, in the opinion of management, necessary in order to make the financial statements not misleading.
Use of Estimates	'
	Use of Estimates
	The preparation of financial statements in conformity with GAAP requires management to adopt accounting policies and make estimates and assumptions that affect amounts reported in the financial statements.  The significant accounting policies, estimates and related judgments underlying the Company’s financial statements are summarized below.  In applying these policies, management makes subjective judgments that frequently require estimates about matters that are inherently uncertain.
Cash and Cash Equivalents	'
	Cash and Cash Equivalents
	The Company considers all investments with a maturity date of three months or less when purchased to be cash equivalents.  There were no cash equivalents at September 30, 2013 and December 31, 2012.
Revenue Recognition	'
	Revenue Recognition
	The Company recognizes revenue on arrangements in accordance with Securities and Exchange Commission Staff Accounting Bulletin Topic 13, Revenue Recognition and FASB ASC 605-15-25, Revenue Recognition.  In all cases, revenue is recognized only when the price is fixed or determinable, persuasive evidence of an arrangement exists, the service is performed and collectability is reasonably assured. The Company did not report any revenues from inception to September 30, 2013.
Earnings Per Share	'
	Earnings Per Share
	The Company has adopted ASC 260-10-50, Earnings Per Share, which provides for calculation of "basic" and "diluted" earnings per share. Basic earnings per share includes no dilution and is computed by dividing net income or loss available to common shareholders by the weighted average common shares outstanding for the period. Diluted earnings per share reflect the potential dilution of securities that could share in the earnings of an entity. Basic and diluted losses per share were the same at the reporting dates as there were no common stock equivalents outstanding at September 30, 2013 and December 31, 2012.
Concentrations	'
	Concentrations
	Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash.
	Occasionally, cash balances may exceed amounts insured by the Federal Deposit Insurance Corporation (“FDIC”).  Accordingly, the Company places its cash and cash equivalents with financial institutions considered by management to be of high credit quality.  At times, the Company’s cash balances may be in excess of the FDIC limits.
Fair Value of Financial Instruments	'
	Fair Value of Financial Instruments
	The Company adopted Statement of Financial Accounting Standards (“SFAS”) No. 157 Fair Value Measurements (“SFAS 157”), superseded by ASC 820-10, which defines fair value, establishes a framework for measuring fair value and expands required disclosure about fair value measurements of assets and liabilities. The impact of adopting ASC 820-10 was not significant to the Company’s financial statements. ASC 820-10 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820-10 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:
	Level 1 – Valuation based on quoted market prices in active markets for identical assets or liabilities.
	Level 2 – Valuation based on quoted market prices for similar assets and liabilities in active markets.
	Level 3 – Valuation based on unobservable inputs that are supported by little or no market activity, therefore requiring management’s best estimate of what market participants would use as fair value.
	In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety.  Our assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment, and considers factors specific to the asset or liability.  The valuation of our derivative liability is determined using Level 1 inputs, which consider (i) time value, (ii) current market and (iii) contractual prices.
	Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of September 30, 2013 and December 31, 2012.  The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments.  These financial instruments include cash, accounts payable, accrued expenses and advance.
Income Taxes	'
	Income Taxes
	Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Additionally, the recognition of future tax benefits, such as net operating loss carryforwards, is required to the extent that realization of such benefits is more likely than not. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which the assets and liabilities are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income tax expense in the period that includes the enactment date.
	In the event the future tax consequences of differences between the financial reporting bases and the tax bases of the Company’s assets and liabilities result in deferred tax assets, an evaluation of the probability of being able to realize the future benefits indicated by such asset is required. A valuation allowance is provided for the portion of the deferred tax asset when it is more likely than not that some or all of the deferred tax asset will not be realized. In assessing the realizability of the deferred tax assets, management considers the scheduled reversals of deferred tax liabilities, projected future taxable income, and tax planning strategies.
	The Company files income tax returns in the United States and Florida, which are subject to examination by the tax authorities in these jurisdictions. Generally, the statute of limitations related to the Company’s federal and state income tax return is three years. The state impact of any federal changes for prior years remains subject to examination for a period up to five years after formal notification to the states.
	Management has evaluated tax positions in accordance with FASB ASC 740, Income Taxes, and has not identified any significant tax positions, other than those disclosed.
Subsequent Events	'
	Subsequent Events
	In accordance with FASB ASC 855, Subsequent Events, the Company evaluated subsequent events through November 11, 2013, the date the financial statements were available for issue.

INTANGIBLE_ASSET_Tables

INTANGIBLE ASSET (Tables)	9 Months Ended
	Sep. 30, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
Schedule of components of intangible assets	'
		September 30,	31-Dec-12
		2013
	License agreement	$6,831	$6,831
	Accumulated amortization	-952	-700
		$5,879	$6,131

TAXES_Tables

TAXES (Tables)	9 Months Ended
	Sep. 30, 2013
Income Tax Disclosure [Abstract]	'
Schedule of components of income tax expense	'
		September 30,	September 30,	Inception to September 30,
		2013	2012	2013
	Current tax benefit	($34,528)	($34,296)	($152,002)
	Change in valuation allowance	34,528	34,296	152,002
		$ -	$ -	$ -
Schedule of difference between income tax expense computed by applying the statutory federal income tax rate	'
		September 30,	September 30,	Inception to September 30,
		2013	2012	2013
	Pretax loss at federal statutory rate	($31,222)	($31,012)	($137,449)
	State income benefit, net of federal benefit	-3,306	-3,284	-14,553
	Change in valuation allowance	34,528	34,296	152,002
		$ -	$ -	$ -
Schedule of components of deferred taxes	'
		September 30,	31-Dec-12
		2013
	Deferred income tax assets:
	Operating loss carryforwards	$152,002	$117,474
	Less: Valuation allowance	-152,002	-117,474
	Net deferred tax asset	$ -	$ -

NATURE_OF_ORGANIZATION_Detail_

NATURE OF ORGANIZATION (Detail Textuals) (Share Exchange Agreement)	1 Months Ended
In Millions, unless otherwise specified	Nov. 29, 2010
Global Green International Inc	'
Nature Of Organization [Line Items]	'
Percentage of ownership acquired	100.00%
Nutritional Health Institute, LLC ("NHIL")	'
Nature Of Organization [Line Items]	'
Percentage of ownership acquired	93.00%
Common stock shares issued under acquisition	683

GOING_CONCERN_Detail_Textuals

GOING CONCERN (Detail Textuals) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Going Concern [Abstract]	'	'
Accumulated Net losses	$404,258	$312,428

INTANGIBLE_ASSET_Components_of

INTANGIBLE ASSET - Components of intangible assets (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Goodwill and Intangible Assets Disclosure [Abstract]	'	'
License agreement	$6,831	$6,831
Accumulated amortization	-952	-700
Intangible asset, net	$5,879	$6,131

INTANGIBLE_ASSET_Detail_Textua

INTANGIBLE ASSET (Detail Textuals)	1 Months Ended
	Nov. 29, 2010
Share Exchange Agreement | Global Green International Inc	'
Finite-Lived Intangible Assets [Line Items]	'
Percentage of ownership acquired	100.00%
Licensing Agreement	'
Finite-Lived Intangible Assets [Line Items]	'
Useful life of the related patent	'20 years

TAXES_Components_of_income_tax

TAXES - Components of income tax expense (Details) (USD $)	9 Months Ended		111 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013
Components of income tax expense	'	'	'
Current tax benefit	($34,528)	($34,296)	($152,002)
Change in valuation allowance	34,528	34,296	152,002
Income tax expense	'	'	'

TAXES_The_difference_between_i

TAXES - The difference between income tax expense computed by applying the statutory federal income tax rate to earnings before taxes (Details 1) (USD $)	9 Months Ended		111 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013
Difference between income tax expense computed by applying the statutory federal income tax rate	'	'	'
Pretax loss at federal statutory rate	($31,222)	($31,012)	($137,449)
State income benefit, net of federal benefit	-3,306	-3,284	-14,553
Change in valuation allowance	34,528	34,296	152,002
Income tax expense	'	'	'

TAXES_Components_of_deferred_t

TAXES - Components of deferred taxes (Details 2) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Income Tax Disclosure [Abstract]	'	'
Operating loss carryforwards	$152,002	$117,474
Less: valuation allowance	-152,002	-117,474
Net deferred tax asset	'	'

TAXES_Detail_Textuals

TAXES (Detail Textuals) (USD $)	Sep. 30, 2013
Income Tax Disclosure [Abstract]	'
Net operating loss carryforwards	$404,258

EQUITY_Detail_Textuals

EQUITY (Detail Textuals) (USD $)	1 Months Ended		111 Months Ended			1 Months Ended
	Mar. 21, 2011	31-May-10	Sep. 30, 2013	Dec. 31, 2012	Apr. 30, 2010	Nov. 29, 2010
						Share Exchange Agreement
						Nutritional Health Institute, LLC ("NHIL")
Stockholders Equity Note [Line Items]	'	'	'	'	'	'
Preferred stock, authorized	'	'	100,000,000	100,000,000	100,000,000	'
Preferred stock, par value	'	'	'	'	'	'
Preferred stock, outstanding	'	'	'	'	'	'
Forward stock split ratio	'	'10-to-1 stock split	'	'	'	'
Par value for forward stock split	'	$0.00	'	'	$0.00	'
Number of common shares issued for services rendered	'	20,000,000	'	'	'	'
Value of common shares issued for services rendered	'	$200	'	'	'	'
Proceeds from share issuance through private placement	$286,000	'	$286,000	'	'	'
Common stock shares issued under acquisition	'	'	'	'	'	683,000,000
Percentage of ownership acquired	'	'	'	'	'	93.00%

RELATED_PARTY_TRANSACTIONS_AND1

RELATED PARTY TRANSACTIONS AND COMMITMENTS (Detail Textuals) (USD $)	Sep. 30, 2013	Jan. 31, 2013	Dec. 31, 2012
Related Party Transaction [Line Items]	'	'	'
Convertible advance - related party	$263,000	'	'
Chief Executive Officer And Chairman | Convertible Debt | Accounts Payable and Accrued Liabilities	'	'	'
Related Party Transaction [Line Items]	'	'	'
Convertible advance, face value	'	300,000	'
Convertible advance, interest rate	'	5.00%	'
Convertible advance - related party	263,000	'	0
Accrued interest	$10,908	'	$0